<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Pre-Clinical Sciences</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F851CB0E-67B4-42AD-B24F-9F5C3DCC9F39"><gtr:id>F851CB0E-67B4-42AD-B24F-9F5C3DCC9F39</gtr:id><gtr:firstName>Cordula</gtr:firstName><gtr:surname>Stover</gtr:surname><gtr:orcidId>0000-0002-0125-4868</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400300"><gtr:id>92D324FD-6E10-4ECC-BDE1-026663117F97</gtr:id><gtr:title>The role of properdin in infection and inflammation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400300</gtr:grantReference><gtr:abstractText>We want to understand more fully the precise role that properdin, a normal blood protein, plays in health and disease. We hope this will clarify key mechanisms and benefit patients with infectious or inflammatory disease. Properdin is an essential component of an amplifying pathway of complement activation, a series of other blood proteins that play a key role in initiating and controlling infection and inflammation. Human deficiency is described and predisposes individuals to meningitis. We are studying mice that are deficient of properdin in models of relevance to public health (bacterial infections and rheumatoid arthritis). We are determining the prevalence and significance of properdin deficiency in human subjects. We are investigating the production of properdin by different classes of white blood cells, and the effects of properdin on some of these cells via certain cell surface receptors, because such interaction may play an important role in regulating white blood cell function in diverse infectious and inflammatory diseases.</gtr:abstractText><gtr:technicalSummary>Properdin is a key molecule of the innate immune response. It stabilises inherently labile convertases of the alternative pathway of complement activation and thereby allows this amplification loop of complement activation to produce the critical mass of activation products required for an effective anti-microbial response. In addition to its protective anti-microbial activity, however, properdin may contribute to the pathophysiology of human disease by perpetuation of overshooting inflammation and tissue destruction. To study both aspects, I have generated a properdin deficient mouse strain which I will investigate in established in vivo models of infectious disease using Listeria monocytogenes and Streptococcus pneumoniae, and of inflammatory disease; i) experimental arthritis and ii) disseminated intravascular coagulation. These experiments will give an indication whether strengthening or weakening of the alternative pathway may be a therapeutic option in human disease. Further, properdin-mediated cellular functions and expression sources will be investigated: Previous work has shown that properdin is synthesised by monocytes, macrophages and T cells and released from mature neutrophils upon stimulation. I will for the first time study the role of properdin in T cell and neutrophil function. Properdin is a secreted plasma protein (5-15microg/ml) but is also abundantly present on the surface of neutrophils. As thrombospondin binds to CD47, I will investigate whether properdin also uses CD47 as a surface receptor, by binding via its thrombospondin motifs. Production of a properdin transgenic mouse with the transgenic protein tagged by Green Fluorescent Protein will allow identification of the very limited number of cell types capable of synthesising and secreting properdin. Lastly, while properdin deficiency has been found in 24 families and in most was linked to increased susceptibility to meningitis, the prevalence of uncharacterised properdin deficiency in a seemingly healthy population is unclear. I will test this by in vitro screening of plasma samples.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-12</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-06-13</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>251223</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>British Satellite News</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>62A5F386-4FF5-4518-98A1-DDDC36245115</gtr:id><gtr:impact>Tite: New discovery on role of vital protein that fights meningitis. http://www2.le.ac.uk/ebulletin/news/press-releases/2000-2009/2008/05/nparticle.2008-05-06.4114851911

Communication from the lay and journalist community</gtr:impact><gtr:outcomeId>EC4427032D8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www2.le.ac.uk/ebulletin/news/press-releases/2000-2009/2008/05/nparticle.2008-05-06.4114851911</gtr:url><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/15/65/31707</gtr:fundingRef><gtr:id>F2C9D0EE-1D3E-4509-9AAD-2B6F3E4A6CF2</gtr:id><gtr:outcomeId>56dabce923c725.77355790</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF funding (Properdin: novel modifier in atherosclerotic plaque formation in mice?)</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>71392B09-9CA8-466B-A9C3-64A2E843C850</gtr:id><gtr:outcomeId>B4869F651CD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society International Joint Project</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>E7BF7715-B961-41AB-8A49-B7766AD071A9</gtr:id><gtr:outcomeId>7238558F5A60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>172000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KR UK project grant</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>University of Leicester</gtr:fundingOrg><gtr:id>DB1F2096-D6EB-4F42-8424-C90F0937DDF1</gtr:id><gtr:outcomeId>sPjpWc5NWMX</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ethical review board appointed 3Rs working group, chair</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>0BA08A86-D4BD-4B48-9F07-F59FA1A0FADF</gtr:id><gtr:impact>additional PG training. 
local policy documents</gtr:impact><gtr:outcomeId>58c273272250d8.26832709</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>the agreement allowed for the previously engineered mouse line to be fully backcrossed to a C57Bl/6 homogenous genetic background, and thereby become suitable for a range of in vivo models. The information on the phenotype of the properdin-deficient mouse line is deposited at the Jackson Laboratory mouse genome website, www.informatics.jax.org/searches/allele_report.cgi?_refs_key=132619</gtr:description><gtr:id>8BE78562-6E31-47DC-926B-894942417631</gtr:id><gtr:impact>A clear understanding of the role of properdin in infection and inflammation, because the phenotype of the deficient mouse or its tissues is compared to that of the wildtype (normal).</gtr:impact><gtr:outcomeId>2E1759F91FF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>properdin-deficient mouse line, C57Bl/6</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:url>http://www.informatics.jax.org/searches/allele_report.cgi?_refs_key=132619</gtr:url><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>77C5FDC8-6666-44C7-AE79-5441E5D31288</gtr:id><gtr:title>Properdin plays a protective role in polymicrobial septic peritonitis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1a7081d061bab4cb140854e4d7c7d88"><gtr:id>e1a7081d061bab4cb140854e4d7c7d88</gtr:id><gtr:otherNames>Stover CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>3BB61B0D97B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>665952A5-CBCD-4AAD-A16A-C23CB3985231</gtr:id><gtr:title>Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e528bf290edeeb8828f680a80e6f9cb"><gtr:id>8e528bf290edeeb8828f680a80e6f9cb</gtr:id><gtr:otherNames>Ruseva MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>pm_15980_20_23184055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11E6F976-20D6-4C1B-B371-77EE921D3A00</gtr:id><gtr:title>Dual role of complement in adipose tissue.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10e5c63026839534b424dc7aeed7dcf2"><gtr:id>10e5c63026839534b424dc7aeed7dcf2</gtr:id><gtr:otherNames>Pattrick M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>82E84FE2B02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0AEECB8-729B-477D-8ACD-C2D83006EA6B</gtr:id><gtr:title>Properdin deficiency in murine models of nonseptic shock.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/178fea7e95ca3a714d690ed006519ba1"><gtr:id>178fea7e95ca3a714d690ed006519ba1</gtr:id><gtr:otherNames>Ivanovska ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>0D2F4515A02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E53CC4DD-7233-4E4A-AFE8-1E9E2C9552D0</gtr:id><gtr:title>The role of properdin in murine zymosan-induced arthritis.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/010ad2a6f0bb79b47e4b61be742d06ea"><gtr:id>010ad2a6f0bb79b47e4b61be742d06ea</gtr:id><gtr:otherNames>Dimitrova P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>rWajAaf8mNv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16DC25CE-AA4E-41D1-A39D-F05DA3B29DB8</gtr:id><gtr:title>Septicaemia models using Streptococcus pneumoniae and Listeria monocytogenes: understanding the role of complement properdin.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/869ccde9bb0d3499f4d158097775c02a"><gtr:id>869ccde9bb0d3499f4d158097775c02a</gtr:id><gtr:otherNames>Dupont A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn><gtr:outcomeId>545505eddfc1a0.75377907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>506A85DD-E86E-45A5-BF35-DC52B51D4936</gtr:id><gtr:title>The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/836f6b24834fedeb0d0d22951a10a6fa"><gtr:id>836f6b24834fedeb0d0d22951a10a6fa</gtr:id><gtr:otherNames>Salehen N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>2C0E38BACF5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A2F4997-8EFF-407A-A62A-D15079F5A18D</gtr:id><gtr:title>Properdin in childhood and its association with wheezing and atopy.</gtr:title><gtr:parentPublicationTitle>Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a7be95755cc15e319748d9f459f3ab7"><gtr:id>3a7be95755cc15e319748d9f459f3ab7</gtr:id><gtr:otherNames>Staley KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0905-6157</gtr:issn><gtr:outcomeId>pm_15980_20_20337960</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400300</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>